OBJECTIVE: Juvenile myoclonic epilepsy (JME) is a common adolescent-onset genetic generalized epilepsy (GGE) syndrome. Multiple linkage and association studies have found that BRD2 influences the expression of JME. The BRD2-JME connection is further corroborated by our murine model; Brd2 haploinsufficiency produces characteristics that typify the clinical hallmarks of JME. Neither we, nor several large-scale studies of JME, found JME-related BRD2 coding mutations. Therefore, we investigated noncoding BRD2 regions, seeking the origin of BRD2's JME influence. BRD2's promoter harbors a JME-associated single nucleotide polymorphism (rs3918149) and a CpG (C-phosphate-G dinucleotides) island (CpG76), making it a potential "hotspot" for JME-associated epigenetic variants. Methylating promoter CpG sites causes gene silencing, often resulting in reduced gene expression. We tested for differences in DNA methylation at CpG76 in 3 different subgroups: (1) JME patients versus their unaffected family members, (2) JME versus patients with other forms of GGE, and (3) Caucasian versus non-Caucasian JME patients. METHODS: We used DNA pyrosequencing to analyze the methylation status of 10 BRD2 promoter CpG sites in lymphoblastoid cells from JME patients of Caucasian and non-Caucasian origin, unaffected family members, and also non-JME GGE patients. We also measured global methylation levels and DNA methyl transferase 1 (DNMT1) transcript expression in JME families by standard methods. RESULTS: CpG76 is highly methylated in JME patients compared to unaffected family members. In families with non-JME GGE, we found no relationship between promoter methylation and epilepsy. In non-Caucasian JME families, promoter methylation was mostly not associated with epilepsy. This makes the BRD2 promoter a JME-specific, ethnicity-specific, differentially methylated region. Global methylation was constant across groups. SIGNIFICANCE: BRD2 promoter methylation in JME, and the lack of methylation in unaffected relatives, in non-JME GGE patients, and in non-Caucasian JME, demonstrate that methylation specificity is a possible seizure susceptibility motif in JME risk and suggests JME therapeutics targeting BRD2. Wiley Periodicals, Inc.
OBJECTIVE:Juvenile myoclonic epilepsy (JME) is a common adolescent-onset genetic generalized epilepsy (GGE) syndrome. Multiple linkage and association studies have found that BRD2 influences the expression of JME. The BRD2-JME connection is further corroborated by our murine model; Brd2haploinsufficiency produces characteristics that typify the clinical hallmarks of JME. Neither we, nor several large-scale studies of JME, found JME-related BRD2 coding mutations. Therefore, we investigated noncoding BRD2 regions, seeking the origin of BRD2's JME influence. BRD2's promoter harbors a JME-associated single nucleotide polymorphism (rs3918149) and a CpG (C-phosphate-G dinucleotides) island (CpG76), making it a potential "hotspot" for JME-associated epigenetic variants. Methylating promoter CpG sites causes gene silencing, often resulting in reduced gene expression. We tested for differences in DNA methylation at CpG76 in 3 different subgroups: (1) JMEpatients versus their unaffected family members, (2) JME versus patients with other forms of GGE, and (3) Caucasian versus non-Caucasian JMEpatients. METHODS: We used DNA pyrosequencing to analyze the methylation status of 10 BRD2 promoter CpG sites in lymphoblastoid cells from JMEpatients of Caucasian and non-Caucasian origin, unaffected family members, and also non-JME GGE patients. We also measured global methylation levels and DNA methyl transferase 1 (DNMT1) transcript expression in JME families by standard methods. RESULTS: CpG76 is highly methylated in JMEpatients compared to unaffected family members. In families with non-JME GGE, we found no relationship between promoter methylation and epilepsy. In non-Caucasian JME families, promoter methylation was mostly not associated with epilepsy. This makes the BRD2 promoter a JME-specific, ethnicity-specific, differentially methylated region. Global methylation was constant across groups. SIGNIFICANCE: BRD2 promoter methylation in JME, and the lack of methylation in unaffected relatives, in non-JME GGE patients, and in non-Caucasian JME, demonstrate that methylation specificity is a possible seizure susceptibility motif in JME risk and suggests JME therapeutics targeting BRD2. Wiley Periodicals, Inc.
Authors: Deb K Pal; Martina Durner; Irene Klotz; Elisa Dicker; Shlomo Shinnar; Stanley Resor; Jeffrey Cohen; Cynthia Harden; Solomon L Moshé; Karen Ballaban-Gill; Edward B Bromfield; David A Greenberg Journal: Brain Dev Date: 2006-01-18 Impact factor: 1.961
Authors: T Sander; B Bockenkamp; T Hildmann; R Blasczyk; R Kretz; T F Wienker; A Volz; B Schmitz; G Beck-Mannagetta; O Riess; J T Epplen; D Janz; A Ziegler Journal: Neurology Date: 1997-09 Impact factor: 9.910
Authors: Deb K Pal; Oleg V Evgrafov; Paula Tabares; Fengli Zhang; Martina Durner; David A Greenberg Journal: Am J Hum Genet Date: 2003-06-25 Impact factor: 11.025
Authors: Aron Gyuris; Diana J Donovan; Kimberly A Seymour; Lindsay A Lovasco; Nathaniel R Smilowitz; Anthony L P Halperin; Jan E Klysik; Richard N Freiman Journal: Biochim Biophys Acta Date: 2009-04-10
Authors: Eilis Hannon; Helen Spiers; Joana Viana; Ruth Pidsley; Joe Burrage; Therese M Murphy; Claire Troakes; Gustavo Turecki; Michael C O'Donovan; Leonard C Schalkwyk; Nicholas J Bray; Jonathan Mill Journal: Nat Neurosci Date: 2015-11-30 Impact factor: 24.884
Authors: Susanna Pagni; James D Mills; Adam Frankish; Jonathan M Mudge; Sanjay M Sisodiya Journal: Neuropathol Appl Neurobiol Date: 2021-12-16 Impact factor: 6.250
Authors: Maxime Gilsoul; Thierry Grisar; Antonio V Delgado-Escueta; Laurence de Nijs; Bernard Lakaye Journal: Front Cell Neurosci Date: 2019-09-27 Impact factor: 5.505
Authors: I M Krzyzewska; S M Maas; P Henneman; K V D Lip; A Venema; K Baranano; A Chassevent; E Aref-Eshghi; A J van Essen; T Fukuda; H Ikeda; M Jacquemont; H-G Kim; A Labalme; S M E Lewis; G Lesca; I Madrigal; S Mahida; N Matsumoto; R Rabionet; E Rajcan-Separovic; Y Qiao; B Sadikovic; H Saitsu; D A Sweetser; M Alders; M M A M Mannens Journal: Clin Epigenetics Date: 2019-11-04 Impact factor: 6.551
Authors: Doretta Caramaschi; Charlie Hatcher; Rosa H Mulder; Janine F Felix; Charlotte A M Cecil; Caroline L Relton; Esther Walton Journal: Clin Epigenetics Date: 2020-01-08 Impact factor: 6.551